Login
Search
Search
0 Dates
2024
2023
2022
2021
2020
2019
2018
0 Events
CPC 2018
CPC 2019
Curso de Atualização em Medicina Cardiovascular 2019
Reunião Anual Conjunta dos Grupos de Estudo de Cirurgia Cardíaca, Doenças Valvulares e Ecocardiografia da SPC
CPC 2020
CPC 2021
CPC 2022
CPC 2023
CPC 2024
0 Topics
A. Basics
B. Imaging
C. Arrhythmias and Device Therapy
D. Heart Failure
E. Coronary Artery Disease, Acute Coronary Syndromes, Acute Cardiac Care
F. Valvular, Myocardial, Pericardial, Pulmonary, Congenital Heart Disease
G. Aortic Disease, Peripheral Vascular Disease, Stroke
H. Interventional Cardiology and Cardiovascular Surgery
I. Hypertension
J. Preventive Cardiology
K. Cardiovascular Disease In Special Populations
L. Cardiovascular Pharmacology
M. Cardiovascular Nursing
N. E-Cardiology / Digital Health, Public Health, Health Economics, Research Methodology
O. Basic Science
P. Other
0 Themes
01. History of Cardiology
02. Clinical Skills
03. Imaging
04. Arrhythmias, General
05. Atrial Fibrillation
06. Supraventricular Tachycardia (non-AF)
07. Syncope and Bradycardia
08. Ventricular Arrhythmias and Sudden Cardiac Death (SCD)
09. Device Therapy
10. Chronic Heart Failure
11. Acute Heart Failure
12. Coronary Artery Disease (Chronic)
13. Acute Coronary Syndromes
14. Acute Cardiac Care
15. Valvular Heart Disease
16. Infective Endocarditis
17. Myocardial Disease
18. Pericardial Disease
19. Tumors of the Heart
20. Congenital Heart Disease and Pediatric Cardiology
21. Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure
22. Aortic Disease
23. Peripheral Vascular and Cerebrovascular Disease
24. Stroke
25. Interventional Cardiology
26. Cardiovascular Surgery
27. Hypertension
28. Risk Factors and Prevention
29. Rehabilitation and Sports Cardiology
30. Cardiovascular Disease in Special Populations
31. Pharmacology and Pharmacotherapy
32. Cardiovascular Nursing
33. e-Cardiology / Digital Health
34. Public Health and Health Economics
35. Research Methodology
36. Basic Science
37. Miscellanea
0 Resources
Abstract
Slides
Vídeo
Report
CLEAR FILTERS
Beta-blockers: a modifier of the natural history of bicuspid aortic valves?
Session:
Comunicações Orais (Sessão 24) - Cardiopatias Congénitas, Doença Vascular Pulmonar e Embolia Pulmonar 2 - Foco no Adulto com Cardiopatia Congénita
Speaker:
Sara Couto Pereira
Congress:
CPC 2022
Topic:
F. Valvular, Myocardial, Pericardial, Pulmonary, Congenital Heart Disease
Theme:
20. Congenital Heart Disease and Pediatric Cardiology
Subtheme:
20.4 Congenital Heart Disease – Treatment
Session Type:
Comunicações Orais
FP Number:
---
Authors:
Sara Couto Pereira; Joana Rigueira; Pedro Silvério António; Joana Brito; Beatriz Valente Silva; Pedro Alves da Silva; Afonso Nunes-Ferreira; Catarina Simões de Oliveira; Ana Margarida Martins; Cláudio David; Fausto j. Pinto; Ana g. Almeida
Abstract
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="color:#000000"><strong><span style="color:black">Introduction: </span></strong><span style="color:black">Bicuspid aortic valve (BAV) disease is one of the most common congenital heart diseases, with an incidence of 0.5–2.0%. In BAV disease, aortic dilatation (AD) is frequent and the use of beta-blockers (BB) and angiotensin receptor blockers (ARB) are expected to slow ascending aorta dilation. In BAV patients (pts) the rule of BB an ARB to prevent AD is not established.</span></span></span></span></p> <p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="color:#000000"><strong><span style="color:black">Purpose: </span></strong><span style="color:black">T</span><span style="color:black">o characterize a population of BAV pts and evaluate the impact of BB and ARB to prevent AD.</span></span></span></span></p> <p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="color:#000000"><strong><span style="color:black">Methods: </span></strong><span style="color:black">Single-center retrospective study of consecutive pts </span><span style="color:black">with isolated BAV documented on the laboratory center echocardiography from 2014 to 2020. Baseline demographic, clinic (including baseline therapy) and echocardiography data were collected. Follow-up (FUP) data of aortic surgery and death were registered. For statistical analysis we performed Chi-Square, Mann-Whitney, Cox regression and survival analysis with Kaplan-Maier curves. </span></span></span></span></p> <p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="color:#000000"><strong><span style="color:black">Results: </span></strong><span style="color:black">We included 250 pts with BAV (mean age 53 ± 15 years, 70.8% males), 148 pts (59.2%) with type 1 Sievers classification, 61 pts (24.4%) with type 2, 9 pts (3.6%) with type 3. Clinical characteristics were similar between groups. At baseline, 114 (45.6%) had AD (root, ascending aorta or both). We observed that BAV type 1 was associated with higher rates of aortic valvopathy: more pts with severe aortic regurgitation (total n= 31; 80.6% type 1 vs 19.4% type 2, p=0.030) and severe aortic stenosis (total n=43; 55.8% type 1 vs 37.2% type 2, p=0.042). On the other hand, we didn’t find any association regarding the phenotype of BAV and presence of AD (p=NS). </span></span></span></span></p> <p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="color:#000000"><span style="color:black">During a mean FUP of 5.6±5.3 years, from 136 pts without previously documented AD, 52 pts (38.2%) developed this complication. At baseline, 46 (34.6%) were under BB and 20 (15%) pts under ARB, while the remaining had no medication. We found that BB therapy was a protective factor for AD during the FUP (LogRank: 4.052, p=0.044), but ARB therapy was not (p=NS).</span></span></span></span></p> <p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="color:#000000"><span style="color:black">Mortality at FUP occurred in 32 pts (15.2%, more frequent in type 1, n=15) with no differences according to phenotypes, AD or valvopathy.</span></span></span></span></p> <p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="color:#000000"><strong><span style="color:black">Conclusions: </span></strong><span style="color:black">The natural history of BAV seems worst in BAV type 1 with more valvopathy, but with no differences in terms of mortality.</span><span style="color:black"> BB therapy seems protective of AD in previous non-dilated aorta in BAV pts. We hypothesize that in BAV pts therapy with BB when started before AD could prevent this complication. A larger study is needed to validate our findings.</span></span></span></span></p>
Slides
Our mission: To reduce the burden of cardiovascular disease
Visit our site